NA89
NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED
11/08/2021
Voltar para busca
Dado oficial do USPTO
QPROTEOME
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
92
Atualização mais recente
11/08/2021
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
1, 5, 9
Data de depósito
13/05/2005
Data de registro
17/05/2011
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
11/08/2021
Última transação
11/08/2021
Escritório responsável
United States Patent and Trademark Office
Código da situação
800
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use, Foreign priority
Código do desenho
4
Tipo de titular
03
Localização do titular
Hilden, DE
Examinador
ENGEL, MICHAEL
Unidade examinadora
L70
Localização atual
GENERIC WEB UPDATE
Titulares e representantes
Titulares
QIAGEN GmbH
QIAGEN GmbH
Representantes
Victoria Friedman Dennemeyer & Associates, LLC
Classificação técnica
Classes Nice
Classe 1Classe 5Classe 9
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 1
Chemicalbiochemical and biotechnical products for industrial and scientific purposessolutions for protein processingprotease inhibitor solutionsdetergent solutionsbuffersreagentsresinsenzymesproteinssolvents for scientificresearchindustrial use; biotechnological productssolutions for protein processingprotease inhibitor solutionsdetergent solutionsbuffersreagentsresinsenzymesproteinssolventsin particular for performing separationisolation and/or purification methods for biopolymersin particular proteinsmacromolecules and biologically active substances for diagnostic purposes; diagnostic preparationsexcept for use in human medicine and veterinary medicine; chemical reagents and solvents except those for purposes in human medicine and veterinary medicine to perform separationisolationand/or purification methods for biopolymersin particular for proteinsmacromolecules and biologically active substances; kits comprising chemical productssolutions for protein processingprotease inhibitors solutionsdetergent solutionsbuffersreagentsresinsenzymesproteinssolventsfor the separation and isolation and/or purification of biopolymersin particular proteinsmacromolecules and biologically active substancesin particular proteins from biological material; cell compartment kits containing extraction buffers and reagents for scientific use; nuclear protein kits containing buffers for isolation and fractionation of nucleic acid binding proteins for scientific use; nuclear subfractionation kits containing buffers for isolation and fractionation of nucleic acid binding proteins for scientific use; total glycoprotein kits containing buffers and reagents for scientific use; mannose glycoprotein kits containing buffers and reagents for scientific use; sialic glycoprotein kits containing buffers and reagents for scientific use; o-glycan glycoprotein kits containing buffers and reagents for scientific use; mitochondria isolation kits containing buffers and reagents for isolation of high-purity mitochondria preparations for scientific use ; plasma membrane protein kits containing buffers and reagents for isolation of plasmamembrane proteins for scientific use; glycoarray kits containing buffers and reagents for scientific use; albumin/IgG depletion kits containing buffers and reagents for scientific use; murine albumin depletion kits containing buffers and reagents for scientific use; bacterial protein prep kits containing buffers and reagents for scientific use; mammalian protein prep kits containing buffers and reagents for scientific use; collection tubes and columns for analysis of glycan makeup and glycoproteins for scientific use
Classe 5
Diagnostic preparations and products for use in human medicine and veterinary medicinesolutions for protein processingprotease inhibitor solutionsdetergent solutionsbuffersreagentsresinsenzymesproteinssolvents for the separationisolation and purification of biopolymersin particular of proteinsmacromolecules and biologically active substances; chemicalbiochemical productssolutions for protein processingprotease inhibitor solutionsdetergent solutionsbuffersreagentsresinsenzymesproteinssolventsin particular for performing separationisolation and/or purification methods for biopolymersin particular proteinsmacromolecules and biologically active substances for medical diagnostic purposes; kits comprising products for medical or veterinary medical diagnostic purposessolutions for protein processingprotease inhibitor solutionsdetergent solutionsbuffersreagentsresinsenzymesproteinssolventsin particular for separationisolation and/or purification of biopolymersin particular of proteinsmacromolecules and biological active substancesin particular of proteins from biological material; cell compartment kits containing extraction buffers and reagents for medical use; nuclear protein kits containing buffers for isolation and fractionation of nucleic acid binding proteins for medical use; nuclear subfractionation kits containing buffers for isolation and fractionation of nucleic acid binding proteins for medical use; total glycoprotein kits containing buffers and reagents for medical use; mannose glycoprotein kits containing buffers and reagents for medical use; sialic glycoprotein kits containing buffers and reagents for medical use; o-glycan glycoprotein kits containing buffers and reagents for medical use; mitochondria isolation kits containing buffers and reagents for isolation of high-purity mitochondria preparations for medical use; plasma membrane protein kits containing buffers and reagents for isolation of plasmamembrane proteins for medical use; glycoarray kits containing buffers and reagents for medical use; albumin/IgG depletion kits containing buffers and reagents for medical use; murine albumin depletion kits containing buffers and reagents for medical use; bacterial protein prep kits containing buffers and reagents for medical use; mammalian protein prep kits containing buffers and reagents for medical use; collection tubes and columns for analysis of glycan makeup and glycoproteins for medical use
Classe 9
Scientific apparatusinstruments and equipmentbinding supportscrystallization supportscolumnstube extenderscollection tubescartridge filters; optical apparatuses and instruments for use in protein processing; calculating machines; electrical and electronic apparatuses and instruments for research and examination purposes for use in protein processing; laboratory equipmentmeasuring apparatus and instruments for medical or veterinary medical diagnostic purposesfor the separationpurificationand/or isolation of biopolymersmacromolecules and biological active substances and proteins from biological materialsoluble protein separation kits containing buffers and reagents for the preparation of separate protein fractions from cleared cell lysates; related computer software for analysis of glycan makeup and glycoproteins
Publicações
Histórico de despachos e eventos da marca no USPTO.
92 publicações encontradas
RNL1
REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)
11/08/2021
89AG
REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED
11/08/2021
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
10/08/2021
E89R
TEAS SECTION 8 & 9 RECEIVED
22/04/2021
REM2
COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
17/05/2020
NA85
NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
10/06/2017
C15P
REGISTERED - PARTIAL SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
10/06/2017
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
09/06/2017
E815
TEAS SECTION 8 & 15 RECEIVED
20/04/2017
REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
17/05/2016
R.PR
REGISTERED-PRINCIPAL REGISTER
17/05/2011
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
01/03/2011
PUBO
PUBLISHED FOR OPPOSITION
01/03/2011
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
21/01/2011
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
14/01/2011
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
14/01/2011
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
14/01/2011
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
14/01/2011
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
03/11/2010
ALIE
ASSIGNED TO LIE
03/11/2010
PAPER RECEIVED
18/10/2010
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
01/10/2010
GNRT
NON-FINAL ACTION E-MAILED
01/10/2010
CNRT
NON-FINAL ACTION WRITTEN
01/10/2010
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
08/09/2010
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
08/09/2010
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
08/09/2010
GPRN
NOTIFICATION OF PRIORITY ACTION E-MAILED
28/07/2010
GPRA
PRIORITY ACTION E-MAILED
28/07/2010
CPRA
PRIORITY ACTION WRITTEN
28/07/2010
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
08/07/2010
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
08/07/2010
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
08/07/2010
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
07/06/2010
GNRT
NON-FINAL ACTION E-MAILED
07/06/2010
CNRT
NON-FINAL ACTION WRITTEN
07/06/2010
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
13/05/2010
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
13/05/2010
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
13/05/2010
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
05/12/2009
GNRT
NON-FINAL ACTION E-MAILED
05/12/2009
CNRT
NON-FINAL ACTION WRITTEN
05/12/2009
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
04/11/2009
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
04/11/2009
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
04/11/2009
UNDC
UNDELIVERABLE MAIL - COURTESY COPY MAILED
26/06/2009
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
25/06/2009
GNRT
NON-FINAL ACTION E-MAILED
25/06/2009
CNRT
NON-FINAL ACTION WRITTEN
25/06/2009
ZZZX
PREVIOUS ALLOWANCE COUNT WITHDRAWN
01/06/2009
PBCR
WITHDRAWN FROM PUB - OG REVIEW QUERY
31/05/2009
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
18/05/2009
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
18/05/2009
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
01/05/2009
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
30/04/2009
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
30/04/2009
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
12/01/2009
GNRT
NON-FINAL ACTION E-MAILED
12/01/2009
CNRT
NON-FINAL ACTION WRITTEN
12/01/2009
ZZZX
PREVIOUS ALLOWANCE COUNT WITHDRAWN
28/11/2008
PBCR
WITHDRAWN FROM PUB - OG REVIEW QUERY
21/11/2008
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
12/11/2008
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
11/11/2008
ACEC
AMENDMENT FROM APPLICANT ENTERED
16/10/2008
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
16/10/2008
PAPER RECEIVED
09/10/2008
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
08/04/2008
GNRT
NON-FINAL ACTION E-MAILED
08/04/2008
CNRT
NON-FINAL ACTION WRITTEN
08/04/2008
ACEC
AMENDMENT FROM APPLICANT ENTERED
15/01/2008
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
15/01/2008
PAPER RECEIVED
07/01/2008
UNDC
UNDELIVERABLE MAIL - COURTESY COPY MAILED
02/07/2007
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
02/07/2007
GNRT
NON-FINAL ACTION E-MAILED
02/07/2007
CNRT
NON-FINAL ACTION WRITTEN
02/07/2007
DOCK
ASSIGNED TO EXAMINER
12/06/2007
ACEC
AMENDMENT FROM APPLICANT ENTERED
23/04/2007
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
23/04/2007
PAPER RECEIVED
20/04/2007
RCSC
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
29/03/2007
ALIE
ASSIGNED TO LIE
29/03/2007
GNSL
LETTER OF SUSPENSION E-MAILED
10/09/2006
CNSL
SUSPENSION LETTER WRITTEN
10/09/2006
ACEC
AMENDMENT FROM APPLICANT ENTERED
29/06/2006
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
19/06/2006
PAPER RECEIVED
19/06/2006
GNRT
NON-FINAL ACTION E-MAILED
19/12/2005
CNRT
NON-FINAL ACTION WRITTEN
19/12/2005
DOCK
ASSIGNED TO EXAMINER
09/12/2005
NWAP
NEW APPLICATION ENTERED
20/05/2005
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace QPROTEOME ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.